The main purpose of this Phase 2 double blind, placebo controlled crossover clinical study is
to demonstrate the efficacy and safety of CXA-10 in obese adult asthmatics. Obesity induces a
chronic systemic inflammatory state characterized by impaired adipokine signaling,
pro-inflammatory cytokine responses, inflammatory cell activation and enhanced generation of
oxidative inflammatory mediators. This impacts the lung, increasing the severity of asthma
and its exacerbations. This research will evaluate how a synthetic nitro-fatty acid (CXA-10,
10-nitro-octadec-9-enoic acid) suppresses the systemic and airway inflammation that
contributes to the obese asthmatic phenotype. Current data support the pleiotropic signaling
actions of CXA-10 to induce adaptive signaling actions that beneficially modulate adipokine
and cytokine expression and inhibit systemic and pulmonary inflammation. The investigators
hypothesize that CXA-10 induced signaling responses will alleviate obesity-related airway
hyperreactivity in obese adult asthmatics.
Phase:
Phase 2
Details
Lead Sponsor:
University of Colorado, Denver
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) National Institutes of Health (NIH)